Recombinant Human Anti-HCMV AD-2S1 epitope of gB Antibody (8F9) (CAT#: PABZ-056)

Figure 1 Dissociation of 8F9 Fab from cells expressing the N‐terminal amino acids (residues 28–100) of gB.

(A) Binding of the 8F9 Fab determined by flow cytometry, with comparisons to unstained cells and cells stained with a secondary anti‐human kappa antibody alone. (B) Binding of the 8F9 Fab to the N‐terminal fragment of gB at time zero and after 2 h of dissociation at 4, 14, 25 and 37°C.

Thomson, C. A., Bryson, S., McLean, G. R., Creagh, A. L., Pai, E. F., & Schrader, J. W. (2008). Germline V‐genes sculpt the binding site of a family of antibodies neutralizing human cytomegalovirus. The EMBO Journal, 27(19), 2592-2602.

Figure 2 ELISA comparing the binding of 8F9, M2J1 and M2J5 Fabs to plates coated with AD-2S1.

Thomson, C. A., Bryson, S., McLean, G. R., Creagh, A. L., Pai, E. F., & Schrader, J. W. (2008). Germline V‐genes sculpt the binding site of a family of antibodies neutralizing human cytomegalovirus. The EMBO Journal, 27(19), 2592-2602.

Figure 3 Anti-HCMV Abs from families I and II bind the AD-2S1 epitope and neutralize HCMV infectivity.

B, The ability of Abs from family I (2B4; closed boxes and open boxes) and family II (8F9; closed circles and open boxes) to block infection of human foreskin fibroblasts by HCMV laboratory strain AD169 (open circles and open boxes) or HCMV clinical isolate 3170 (closed circles and closed boxes). Abs were serially diluted starting at 15 μg/ml to determine the concentration required for 50% inhibition of infectivity (IC₅₀).

McLean, G. R., Olsen, O. A., Watt, I. N., Rathanaswami, P., Leslie, K. B., Babcook, J. S., & Schrader, J. W. (2005). Recognition of human cytomegalovirus by human primary immunoglobulins identifies an innate foundation to an adaptive immune response. The Journal of Immunology, 174(8), 4768-4778.